Needham Reiterates Buy on Cara Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Cara Therapeutics (NASDAQ:CARA) and maintained a $5 price target.
March 05, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Cara Therapeutics with a $5 price target.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst suggests a positive outlook on CARA's stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100